2023 FDA-approved psychotropic medications

Ahmed Naguy; Nadyah Alayadhi; Saxby Pridmore; Hessa Alhazeem; Bibi Alamiri

doi:10.1016/j.ajp.2023.103684

2023 FDA-approved psychotropic medications

Asian J Psychiatr. 2023 Sep:87:103684. doi: 10.1016/j.ajp.2023.103684. Epub 2023 Jun 23.

Authors

Ahmed Naguy¹, Nadyah Alayadhi², Saxby Pridmore³, Hessa Alhazeem⁴, Bibi Alamiri⁵

Affiliations

¹ Al-Manara CAP Centre, Kuwait Centre for Mental Health (KCMH), Jamal Abdul-Nassir St, Shuwaikh, Kuwait. Electronic address: ahmednagy@hotmail.co.uk.
² Pharmacy Department, KCMH, Kuwait.
³ Discipline of Psychiatry, University of Tasmania, Hobart, Tasmania, Australia; TMS Unit, Saint Helens Private Hospital, Hobart, Tasmania, Australia.
⁴ Faculty of Medicine, Kuwait University, Kuwait.
⁵ Al-Manara CAP Centre, KCMH, Kuwait; Tufts University, Medford, United States.

PMID: 37379646
DOI: 10.1016/j.ajp.2023.103684

Abstract

As of June 2023, (US) FDA has granted approval for a number of psychotropic drugs on market that might usher an innovative sparkle in psychopharmacotherapy. This is a recap to update busy clinicians.

Keywords: Psychopharmacology; Updates.

Publication types

Letter

MeSH terms

Drug Approval*
Humans
Psychotropic Drugs* / therapeutic use
United States
United States Food and Drug Administration

Substances

Psychotropic Drugs